Jump to main content.

Bentazon (Basagran) Quickview (CASRN 25057-89-0)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Bentazon (Basagran)

File First On-Line: 03/03/1987; Last Significant Revision: 03/02/1998

Category (section)
Last Revised
Oral RfD Assessment Yes 03/02/1998
Inhalation RfC Assessment Message 03/02/1998
Carcinogenicity Assessment Yes 03/02/1998
  • 25057-89-0
  • BAS 351-H
  • Basagran
  • Bendioxide
  • Bentazon
  • Bentazone
  • 1 h-2,1,3-Benzothiadiazin-4 (3h)-one-2,2-dioxide, 3-isopropyl-
  • 3-Isopropyl-2,1,3-benzothiadiazinon-(4)-2,2-dioxid
  • 3-Isopropyl-1 h-2, 1-3-benzothiadiazin-4(3h)-one-2,2-dioxide
  • 3-(1-Methylethyl)-1h-2,1,3-benzothiazain-4(3h)-one,2,2-dioxide
  • Bentazon (Basagran)
Bentazon (Basagran) Source Documents
Revision History
Date Section Description
03/02/1998 I.A., II., VI. New RfD, cancer assessment
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect. ) NOAEL (ADJ): 3.2 mg/kg-day 100 3.0 x10-2 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • E (Evidence of non-carcinogenicity for humans)
    • Not likely to be carcinogenic to humans
  • Weight-of-Evidence Narrative:
    • Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.